Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...
MADRID -- Extended low-dose apixaban (Eliquis) after venous thromboembolism (VTE) provoked by events like trauma or surgery in patients with obesity or other enduring risk factors dramatically reduced ...
Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...
In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...
Please provide your email address to receive an email when new articles are posted on . Reduced dosing of direct oral anticoagulants for VTE conferred comparable efficacy as full dosing. Reduced ...
Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced an agreement with the U.S. government to provide Eliquis® (apixaban), an oral anticoagulant relied upon by millions of Americans daily, for free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results